The study will assess autonomic function in predicting coronary artery disease (CAD) and its relationship to depression, as well as long-term outcomes.
The ECG patch features an electrocardiography sensor and accelerometer capable of capturing and generating multiple physiological data, including ECG trace, heart rate, RR-interval and 3-axis motion.
The patch weighs around 7.5g and can be reused and recharged. After 72 hours of continuous wear, data can be captured and transmitted in real-time.
Emory University Rollins School of Public Health Epidemiology assistant professor Amit Shah said: “VivaLNK’s ECG patch is very small and comfortable to wear, which are important factors for clinical use and long-term ECG monitoring.
“In addition, the software development kit makes it easy to use the patch for research and product development purposes.”
During the trial, researchers can remotely monitor patients undergoing coronary angiography using the ECG patch to measure autonomic function.
Patients will be continuously observed for 72 hours within a clinical and ambulatory atmosphere, providing a complete representation in a natural setting.
The research is aimed to provide a better understanding of the role of the autonomic nervous system during depression and CAD.
Furthermore, the research will pave the way for the development of better tools for clinical assessment.
In December 2017, VivaLNK unveiled its Vital Scout assessment patch with electrocardiography (ECG) and three-dimensional (3D) accelerometer sensors to monitor vital signs.
The patch leverages the company’s breathable and non-invasive eSkin technology, a thin electronic substrate used for sensor integration and data services.